

# Program Announcement

Department of Defense Congressionally Directed Medical Research Programs

Amyotrophic Lateral Sclerosis Research Program

Therapeutic Idea Award

Funding Opportunity Number: W81XWH-10-ALSRP-TIA

## TABLE OF CONTENTS

<b>I.</b>	<b>Funding Opportunity Description.....</b>	<b>2</b>
	A. Program Description.....	2
	B. Award Description .....	2
	C. Eligibility.....	3
	D. Funding.....	3
	E. Award Administration.....	4
<b>II.</b>	<b>Timeline for Submission and Review.....</b>	<b>4</b>
<b>III.</b>	<b>Submission Process .....</b>	<b>4</b>
	A. Step 1 – Pre-Application Components .....	4
	B. Step 2 – Application Components.....	6
<b>IV.</b>	<b>Information for Application Review .....</b>	<b>9</b>
	A. Application Review and Selection Overview .....	9
	B. Review Criteria.....	10
<b>V.</b>	<b>Administrative Actions.....</b>	<b>11</b>
<b>VI.</b>	<b>Contact Information .....</b>	<b>13</b>
<b>VII.</b>	<b>Application Submission Checklist.....</b>	<b>14</b>

## I. FUNDING OPPORTUNITY DESCRIPTION

### A. Program Description

The Amyotrophic Lateral Sclerosis Research Program (ALSRP) was established in 2007 to provide support for research of exceptional scientific merit aimed at preclinical assessment of therapeutics for amyotrophic lateral sclerosis (ALS). Appropriations for the ALSRP from fiscal year 2007 (FY07) through FY09 totaled \$10 million (M). The FY10 appropriation is \$7.5M.

The goal of the ALSRP is to promote the introduction of improved therapies for ALS by encouraging ALS investigators to undertake preclinical studies of novel and existing agents.

### B. Award Description

The ALSRP Therapeutic Idea Award mechanism is being offered for the first time in FY10.

The Therapeutic Idea Award is designed to promote new ideas that are still in the early stages of development with the potential to yield highly impactful data and new avenues of investigation for novel therapeutics for ALS treatment. This mechanism supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancement in ALS therapeutics. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale.

***Presentation of preliminary data is not consistent with the intent of the Therapeutic Idea Award mechanism. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data.***

Innovation and Impact are the most important aspects of the Therapeutic Idea Award.

**Innovation:** Research deemed innovative may introduce a new paradigm, challenge current paradigms, introduce novel concepts or agents, or exhibit other uniquely creative qualities that may lead to potential therapeutics for ALS.

The following list, ***although not all-inclusive***, provides examples of research that is NOT innovative and will not be considered for funding under this mechanism:

- Investigating the next logical step or continuation of a previous research project.
- Proposing work that is an incremental advancement of published data.
- Proposing a project whose scope is primarily small molecule or genomic/proteomic screening.
- Exploring a previously tested hypothesis in a different cell line or in a new population.
- Using a published series of in vitro assays to further characterize a model system.
- Incorporating known biomarkers into in vitro or clinical models of ALS.

**Impact:** Describes research that has high potential to significantly impact development of therapeutics for ALS.

**Use of human subjects and human biological substances:** Because these awards are designed for basic pre-clinical research, projects involving human subjects or specimens will not be supported unless they are exempt under Title 32, Code of Federal Regulations, Part 219, Section 101(b) (32 CFR 219.101[b]). *Studies that do not qualify for exempt status during review at any level will be administratively withdrawn and will not be funded.* Additional information regarding exempt status may be found on the US Army Medical Research and Materiel Command (USAMRMC) Human Research Protection Office website (<https://mrmc.amedd.army.mil/rodorphrpo.asp>) and the Application Instructions and General Information, Appendix 5, for this award mechanism.

### C. Eligibility

Investigators at all academic levels (or equivalent) are eligible to submit applications. Refer to General Application Instructions, Appendix 1, for general eligibility information.

### D. Funding

- The maximum period of performance is **2** years.
- The maximum allowable funding for the entire period of performance is **\$400,000** in direct costs.
- The applicant may request the entire maximum direct cost amount for a project that may be less than the maximum 2-year period of performance.
- Regardless of the period of performance proposed, the applicant may not exceed the maximum direct cost. In addition to the direct costs, indirect costs may be proposed in accordance with the organization's negotiated rate agreement.

Within the guidelines provided in the General Application Instructions, funds can cover:

- Salary
- Research supplies
- Equipment
- Clinical research costs
- Support for multidisciplinary collaborations
- Travel between collaborating organizations
- Travel funds must be requested for the PI to attend one DOD military research-related meeting to be determined by the Office of the Congressionally Directed Medical Research Programs (CDMRP) during the award performance period.
- Travel costs of up to \$1,800 USD per year to attend scientific/technical meetings
- Other direct costs as described in the General Application Instructions for the Detailed Budget and Justification

*The Office of the Congressionally Directed Medical Research Programs (CDMRP) expects to allot approximately \$1.92M of the \$7.5M FY10 ALSRP appropriation to fund approximately 3 Therapeutic Idea Award applications, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement/ Funding Opportunity is contingent upon the availability of Federal funds for this program.*

#### **E. Award Administration**

Awards will be made approximately 4 to 6 months after receiving a funding notification letter, but no later than September 30, 2011. Refer to the General Application Instructions, Appendix 4, for general award administration information.

## **II. TIMELINE FOR SUBMISSION AND REVIEW**

- **Pre-application Submission Deadline: 5:00 p.m. Eastern time (ET), May 14, 2010**
- **Invitation to Submit an Application: June 2010**
- **Application Submission Deadline: 11:59 p.m. ET, August 4, 2010**
- **Scientific Peer Review: September 2010**
- **Programmatic Review: December 2010**

*Application submissions will not be accepted unless the pre-application process is completed by the pre-application deadline.*

## **III. SUBMISSION PROCESS**

Submission is a two-step process requiring both (1) pre-application submission through the CDMRP eReceipt system (<https://cdmrp.org/>) and (2) application submission through Grants.gov (<http://www.grants.gov/>). *Applications will be invited based on pre-application screening.*

Submission of the same research project to different funding opportunities within the same program and fiscal year is discouraged. The Government reserves the right to reject duplicative applications.

Principal Investigators (PIs) and organizations identified in the application should be the same as those identified in the pre-application. If a change in PI or organization is necessary after submission of the pre-application, the PI must contact the eReceipt help desk at [help@cdmrp.org](mailto:help@cdmrp.org) or 301-682-5507.

### **A. Step 1 – Pre-Application Components**

All pre-application components must be submitted through the CDMRP eReceipt system by **5:00 p.m. ET on the deadline**. Because the invitation to submit an application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

The pre-application consists of the following components, which are organized in the CDMRP eReceipt system by separate tabs (Refer to the General Application Instructions for additional information on pre-application submission):

- **Proposal Information – Tab 1**
- **Proposal Contacts – Tab 2**
- **Collaborators and Conflicts of Interest (COI) – Tab 3**
- **Required Files – Tab 4**

**Preproposal Narrative (two-page limit):** The Preproposal Narrative is inclusive of any figures, tables, graphs, photographs, diagrams, chemical structures, pictures, pictorials, and cartoons.

The Preproposal Narrative should include the following:

- **Research Idea:** State the ideas and reasoning on which the proposed work is based.
- **Research Strategy:** Concisely state the project's objectives and specific aims.
- **Innovation:** Describe how the project may introduce a new paradigm, challenge current paradigms, introduce novel concepts or agents, or exhibit other uniquely creative qualities that may lead to potential therapeutics for ALS.
- **Impact:** State explicitly how the proposed work will have an impact on the development of therapeutics for ALS.

**Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application are limited to:

- **References Cited (one-page limit):** List relevant references using a standard reference format that includes the full citation (i.e., author(s), year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate). The inclusion of Internet URLs to references is encouraged.

- **Submit Pre-application – Tab 5**

**Pre-Application Screening:** Pre-applications will be screened by the ALSRP Integration Panel (IP), composed of scientists, clinicians, and consumer advocates. The pre-application screening criteria are as follows:

- **Research Idea:** How the proposed research will advance development of therapeutics for ALS.
- **Research Strategy:** How the specific aims are feasible and support the research idea.
- **Innovation:** How the project may introduce a new paradigm, challenge current paradigms, introduce novel concepts or agents, or exhibit other uniquely creative qualities that may lead to potential therapeutics for ALS.
- **Impact:** How the proposed work will have an impact on the development of therapeutics for ALS.

Following the pre-application screening, PIs will be notified of whether or not they are invited to submit an application; however, they will not receive feedback (e.g., strengths and weaknesses) on their pre-application.

## **B. Step 2 – Application Components**

*Applications will not be accepted unless the PI has received a letter of invitation.*

Applications are submitted by the Authorized Organizational Representative (AOR) through Grants.gov (<http://www.grants.gov/>). Applications must be submitted **by 11:59 p.m. ET on the deadline.**

Each application submission must include the completed application package of forms and attachments identified in Grants.gov for this Program Announcement/Funding Opportunity.

The Grants.gov application package consists of the following components (Refer to the General Application Instructions, Section II.B., for additional information on application submission):

**1. SF 424 (R&R) Application for Federal Assistance Form:** Refer to the General Application Instructions, Section II.B., for detailed information.

### **2. Attachments Form**

- **Attachment 1: Project Narrative (eight-page limit):** Upload as “ProjectNarrative.pdf.”

Throughout the Project Narrative, describe how the proposed research is innovative and the potential impact it may have on ALS therapeutics. Presentation of preliminary data is not required. However, PIs must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the proposal to be competitive.

Describe the proposed project using the following outline:

- **Background:** Present the ideas and reasoning behind the proposed work. Cite relevant literature.
- **Hypothesis or Objective:** State the hypothesis to be tested or the objective(s) to be reached.
- **Specific Aims:** Concisely explain the project’s specific aims and their relevance to the study objective(s).
- **Research Strategy:** Describe the experimental design, methods, and analyses including appropriate controls in sufficient detail for analysis. Describe the statistical plan, if appropriate, for the research proposed. Address potential problem areas and present alternative methods and approaches.

- **Attachment 2: Supporting Documentation.** Start each document on a new page. Combine and upload as a single file named “Support.pdf.” If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. *Each component has no page limit unless otherwise noted.*
  - References Cited: List all relevant references using a standard reference format that includes the full citation (i.e., author(s), year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate). The inclusion of Internet URLs to references is encouraged.
  - List of Acronyms and Symbols: Provide a list of acronyms and symbols (e.g., PCR = polymerase chain reaction).
  - Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the US Army Medical Research and Materiel Command (USAMRMC). Indicate if Government-owned facilities or equipment are proposed for use. Reference should be made to the original or present contract under which the facilities or equipment items are now accountable. There is no form for this information.
  - Publications and/or Patent Abstracts (five-document limit): Include relevant publication URLs and/or patent abstracts. If publications are not publicly available, then they must be included. Extra items will not be reviewed.
  - Letters of Organizational Support (two-page limit per letter): Provide a letter (or letters if applicable), signed by the Department Chair or appropriate organization official, reflecting the laboratory space, equipment, and other resources available for the project.
  - Letters of Collaboration (if applicable) (two-page limit per letter): Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work.
  - Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.
- **Attachment 3: Technical Abstract (one-page limit):** Upload as “TechAbs.pdf.” Use the outline below.
  - Background: Present the ideas and reasoning behind the proposed work.
  - Objective/Hypothesis: State the objective/hypothesis to be tested. Provide evidence or rationale that supports the objective/hypothesis.
  - Specific Aims: State the specific aims of the study.
  - Study Design: Briefly describe the study design including appropriate controls.
  - Impact: Summarize briefly how the proposed project will impact development of therapeutics for ALS.

- **Attachment 4: Public Abstract (one-page limit):** Upload as “PublicAbs.pdf.”  
Clearly describe, in a manner readily understood by laypersons, the rationale and objective for the proposal. Do not duplicate the technical abstract.  
Describe the ultimate applicability of the research.
  - What types of patients will it help and how will it help them?
  - What are the potential clinical applications, benefits, and risks?
  - What is the projected time it may take to achieve a patient-related outcome?
  - If the research is too basic for clinical applicability, describe the interim outcomes.
  - What are the likely contributions of this study in advancing development of therapeutics for ALS?
- **Attachment 5: Statement of Work (SOW) (three-page limit):** Upload as “SOW.pdf.” Refer to the General Application Instructions, Section II.B., for detailed information.
- **Attachment 6: Detailed Budget and Justification (no page limit):** Upload as “Budget.pdf.” Use the Detailed Budget and Justification form (available for download on the Full Announcement page in Grants.gov). Refer to the General Application Instructions, Section II.B., for detailed information.
- **Attachment 7: Subaward Detailed Budget and Justification (if applicable) (no page limit):** Use a separate Detailed Budget and Justification form for each subaward budget. Combine into a single file and upload as “SubBudgets.pdf.” Refer to the General Application Instructions, Section II.B., for detailed information.
- **Attachment 8: Impact Statement (one-page limit):** Upload as “Impact.pdf.” Describe the ultimate vision for how the proposed work, if successful, will impact the development of therapeutics for ALS.
- **Attachment 9: Innovation Statement (one-page limit):** Upload as “Innovation.pdf.” Summarize how the proposal is innovative. Investigating the next logical step or incremental advancement on published data is not considered innovative. The following examples of ways in which proposals may be innovative, *although not all-inclusive*, are intended to help PIs frame the innovative features of their proposals:
  - Study concept: Investigation of a novel idea and/or research question.
  - Research method or technology: Use of novel research methods or new technologies, including technology development, to address a research question.
  - Clinical interventions: Use of a novel method or technology for preventing, detecting, diagnosing, or treatment.
  - Existing methods or technologies: Application or adaptation of existing methods or technologies for novel research or clinical purposes, or for research or clinical purposes that differ fundamentally from those originally intended.

**3. Research & Related Senior/Key Person Profile (Expanded) Form:** Refer to the General Application Instructions, Section II.B., for detailed information.

- PI Biographical Sketch (four-page limit): Upload as “Biosketch\_LastName.pdf.”
- PI Current/Pending Support (no page limit): Upload as “Support\_LastName.pdf.”
- Key Personnel Biographical Sketches (four-page limit each): Upload as “Biosketch\_LastName.pdf.”
- Key Personnel Current/Pending Support (no page limit): Upload as “Support\_LastName.pdf.”

**4. Project/Performance Site Location(s) Form:** Refer to the General Application Instructions, Section II.B., for detailed information.

#### **IV. INFORMATION FOR APPLICATION REVIEW**

##### **A. Application Review and Selection Overview**

All applications are evaluated by scientists, clinicians, and consumer advocates using a two-tier review process. The first tier is a scientific peer review of applications against established criteria for determining scientific merit. The second tier is a programmatic review that compares applications to each other and makes recommendations for funding to the Commanding General, USAMRMC, based on scientific merit, the overall goals of the program, and specific intent of the award mechanism. The highest scoring applications from the first tier of review are not automatically recommended for funding. Additional information about the two-tier review process used by the CDMRP may be found at <http://cdmrp.army.mil/fundingprocess.htm>.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Each level of review requires panelists to sign a non-disclosure statement attesting that application and evaluation information will not be disclosed outside the panel. Violations of the non-disclosure statement can result in the dissolving of a panel(s) and other corrective actions. Organizational personnel and PIs are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panelists or PIs that compromise the confidentiality of the review process may also result in suspension or debarment of their employing organizations from Federal awards. Furthermore, it is a crime for Federal officials to disclose confidential information of one party to another third party (Title 18 United States Code 1905).

## **B. Review Criteria**

**1. Peer Review:** All applications will be evaluated according to the following criteria, which are listed in decreasing order of importance:

- **Innovation**
  - How the research proposes new paradigms or challenges existing paradigms in one or more of the following ways: Concept or question, research methods or technologies, or adaptations of existing methods or technologies that will lead to new therapies for ALS.
  - How the application describes a new research idea and not the next logical step or continuation of a previous research project.
  - How the proposed research represents more than an incremental advance upon published data.
  - How the proposed research introduces a novel concept or agent for treatment of ALS.
- **Impact**
  - How the research, if successful, might make a significant contribution toward the development of therapeutics for ALS.
  - How the potential gain warrants the perceived risk.
- **Research Strategy and Feasibility**
  - How the scientific rationale supports the project and its feasibility, as demonstrated by a critical review and analysis of the literature and/or by logical reasoning.
  - How well the hypotheses or objectives, aims, experimental design, methods, and analyses are developed and integrated into the project.
  - How well the PI acknowledges potential problems and addresses alternative approaches.

The following will not be individually scored, but may impact the overall evaluation of the application:

- **Personnel**
  - How the PI, the research team, and any collaborators' background and expertise are appropriate to accomplish the proposed work.
  - How the levels of effort are appropriate for successful conduct of the proposed work.
- **Environment**
  - How the scientific environment is appropriate for the proposed research.
  - How the research requirements are supported by the availability of and accessibility to facilities and resources.

- How the quality and extent of organizational support are appropriate for the proposed research.
- **Budget**
  - Whether the budget is appropriate for the proposed research and within the limitations of this Program Announcement/Funding Opportunity.
- **Application Presentation**
  - How the writing and components of the application influenced the review.

**2. Programmatic Review:** The following equally weighted criteria are used by programmatic reviewers to make funding recommendations:

- Ratings and evaluations of the peer reviewers
- Programmatic relevance
- Relative innovation and impact
- Program portfolio composition
- Adherence to the intent of the award mechanism

## **V. ADMINISTRATIVE ACTIONS**

After receipt of pre-applications from CDMRP eReceipt or applications from Grants.gov, the following administrative actions may occur:

### **A. Rejection**

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative exceeds page limit.
- Preproposal Narrative is missing.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).

The following will result in administrative rejection of the application:

- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- The PI does not meet the eligibility criteria as described in this Program Announcement/Funding Opportunity.
- Submission of an application for which a letter of invitation was not sent.
- Submission of an application for which a pre-application was not submitted.

## **B. Modifications**

- Pages exceeding the specified limits will be removed prior to review for all documents other than the Project Narrative and Preproposal Narrative.
- Documents not requested will be removed.
- Following the application deadline, you may be contacted by CDMRP via email with a request to provide certain missing supporting documents (excluding those listed in Section V-A, Rejection). The missing documents must be provided by 5:00 p.m. ET on the second full business day following the date the email was sent. Otherwise, the application will be reviewed as submitted.

## **C. Withdrawal**

The following may result in administrative withdrawal of the application:

- FY10 ALSRP IP member(s) is found to be involved in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting document. A list of the FY10 ALSRP IP members may be found at <http://cdmrp.army.mil/alsrp/panel10.htm>.
- Submission of the same research project to different funding opportunities within the same program and fiscal year.
- The application does not conform to this Program Announcement/Funding Opportunity description to an extent that precludes appropriate review.
- Direct costs as shown on the detailed budget form exceed maximum allowed by this Program Announcement/Funding Opportunity.
- Inclusion of URLs with the exception of links to published references.

## **D. Withhold**

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be requested to provide the findings of the investigation to the US Army Medical Research Acquisition Activity (USAMRAA) Contracting/Grants Officer for a determination of the final disposition of the application.

## VI. CONTACT INFORMATION

**A. CDMRP Program Announcement Help Desk:** Questions related to Program Announcement/Funding Opportunity content or submission requirements should be directed to the CDMRP Program Announcement help desk, which is available Monday through Friday from 7:30 a.m. to 4:00 p.m. ET. Submit questions as early as possible. Response times will vary depending upon the volume of inquiries. Every effort will be made to answer questions within 5 working days.

Phone: 301-619-7079  
Email: [cdmrp.pa@amedd.army.mil](mailto:cdmrp.pa@amedd.army.mil)

**B. CDMRP eReceipt System Help Desk:** Questions related to the submission of the pre-application through the eReceipt system should be directed to the CDMRP eReceipt system help desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET.

Phone: 301-682-5507  
Email: [help@cdmrp.org](mailto:help@cdmrp.org)

**C. Grants.gov Contact Center:** Questions related to application submission through the Grants.gov portal should be directed to Grants.gov help desk, which is available 24 hours a day, 7 days a week. Please note that the CDMRP Program Announcement and eReceipt system help desks are unable to provide technical assistance regarding Grants.gov submissions.

Phone: 800-518-4726  
Email: [support@grants.gov](mailto:support@grants.gov)

***Sign up on Grants.gov for “send me change notification emails” by following the link on the Synopsis page for the Program Announcement/Funding Opportunity. If the application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.***

## VII. APPLICATION SUBMISSION CHECKLIST

<b>Grants.gov Application Components</b>	<b>Action</b>	<b>Completed</b>
SF-424 (R&R) Application for Federal Assistance Form	Complete form as instructed	
Attachments Form	Upload Project Narrative (ProjectNarrative.pdf) as Attachment 1	
	Upload Supporting Documentation (Support.pdf) as Attachment 2	
	Upload Technical Abstract (TechAbs.pdf) as Attachment 3	
	Upload Public Abstract (PublicAbs.pdf) as Attachment 4	
	Upload Statement of Work (SOW.pdf) as Attachment 5	
	Upload Detailed Budget and Justification (Budget.pdf) as Attachment 6	
	Upload Subaward Detailed Budget and Justification (SubBudgets.pdf) as Attachment 7	
	Upload Impact Statement (Impact.pdf) as Attachment 8	
	Upload Innovation Statement (Innovation.pdf) as Attachment 9	
	Research & Related Senior/Key Person Profile (Expanded)	Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field
Attach PI Current & Pending Support (Support_LastName.pdf) to the appropriate field		
Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field		
Attach Current & Pending Support (Support_LastName.pdf) for each senior/key person to the appropriate field		
Project/Performance Site Location(s) Form	Complete form as instructed	

Principal Investigator:

CDMRP Log Number:

## Detailed Budget and Justification

Name of Principal Investigator: \_\_\_\_\_

CDMRP log number: \_\_\_\_\_ *Last Name* \_\_\_\_\_ *First Name* \_\_\_\_\_ *Middle Name* \_\_\_\_\_ *Suffix*

Period of Performance: From: \_\_\_\_\_ Through: \_\_\_\_\_

<b><i>DETAILED BUDGET FOR YEAR ONE</i></b>							
<b>SENIOR/KEY PERSON &amp; OTHER PERSONNEL</b>		<b>TYPE APPT. (MONTHS)</b>	<b>ANNUAL BASE SALARY</b>	<b>EFFORT ON PROJECT</b>	<b>DOLLAR AMOUNT REQUESTED (OMIT CENTS)</b>		
<b>NAME</b>	<b>ROLE ON PROJECT</b>				<b>SALARY REQUESTED</b>	<b>FRINGE BENEFITS</b>	<b>TOTALS</b>
	Principal Investigator						

<b>A. SUBTOTAL PERSONNEL COSTS</b>			
------------------------------------	--	--	--

## Detailed Budget and Justification

<b><u>DETAILED BUDGET FOR YEAR ONE (CONTINUED)</u></b>	
<b><u>OTHER DIRECT COSTS</u></b>	
MAJOR EQUIPMENT (ITEMIZE)	
TRAVEL COSTS	
MATERIALS, SUPPLIES, AND CONSUMABLES (ITEMIZE BY CATEGORY)	
CONSULTANT COSTS	
SUBAWARD/CONSORTIUM/CONTRACTUAL COSTS (ITEMIZE, INCLUDE TOTAL COSTS INCLUDING DIRECT AND INDIRECT COSTS)	
RESEARCH-RELATED SUBJECT COSTS	
OTHER EXPENSES (ITEMIZE BY CATEGORY)	
<b>B. SUBTOTAL OTHER DIRECT COSTS FOR INITIAL BUDGET PERIOD</b>	
<b>C. TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD (A+B)</b>	
<b>D. TOTAL INDIRECT COSTS FOR INITIAL BUDGET PERIOD</b>	
<b>TOTAL COSTS FOR INITIAL BUDGET PERIOD (C+D)</b>	

## Detailed Budget and Justification

<b><u>BUDGET FOR ENTIRE PROPOSED PERIOD OF PERFORMANCE</u></b>						
<b>BUDGET CATEGORY TOTALS*</b>	<b>BUDGET YEAR ONE</b>	<b>ADDITIONAL YEARS OF SUPPORT REQUESTED</b>				<b>TOTAL</b>
		<b>2nd</b>	<b>3rd</b>	<b>4th</b>	<b>5th</b>	
<b>A. PERSONNEL COSTS</b>						
SALARY REQUESTED						
FRINGE COSTS						
<b>B. OTHER COSTS</b>						
MAJOR EQUIPMENT						
TRAVEL COSTS						
MATERIALS, SUPPLIES, AND CONSUMABLES						
CONSULTANT COSTS						
SUBAWARD/CONSORTIUM/ CONTRACTUAL COSTS						
RESEARCH-RELATED SUBJECT COSTS						
OTHER EXPENSES						
<b>C. TOTAL DIRECT COSTS</b>						
<b>D. TOTAL INDIRECT COSTS</b>						
<b>TOTAL DIRECT COSTS FOR ENTIRE PROPOSED PERIOD OF SUPPORT</b>						
<b>TOTAL INDIRECT COSTS FOR ENTIRE PROPOSED PERIOD OF SUPPORT</b>						
<b>TOTAL COSTS FOR THE ENTIRE PROPOSED PERIOD OF SUPPORT</b> <small>THIS AMOUNT MUST MATCH WITH THAT ENTERED ON THE SF 424, BLOCK 16A</small>						

\* Itemize all budget categories for additional years on the Justification page that follows.

*Principal Investigator:*

*CDMRP Log Number:*

## **Detailed Budget and Justification**

### **JUSTIFICATION**

**FOLLOW THE BUDGET JUSTIFICATION INSTRUCTIONS EXACTLY. USE CONTINUATION PAGES AS NEEDED.**

*Principal Investigator:*

*CDMRP Log Number:*

## **Detailed Budget and Justification**

### **JUSTIFICATION**

**FOLLOW THE BUDGET JUSTIFICATION INSTRUCTIONS EXACTLY. USE CONTINUATION PAGES AS NEEDED.**

*Principal Investigator:*

*CDMRP Log Number:*

## **Detailed Budget and Justification**

### **JUSTIFICATION**

**FOLLOW THE BUDGET JUSTIFICATION INSTRUCTIONS EXACTLY. USE CONTINUATION PAGES AS NEEDED.**

*Principal Investigator:*

*CDMRP Log Number:*

## **Detailed Budget and Justification**

### **JUSTIFICATION**

**FOLLOW THE BUDGET JUSTIFICATION INSTRUCTIONS EXACTLY. USE CONTINUATION PAGES AS NEEDED.**

*Principal Investigator:*

*CDMRP Log Number:*

## **Detailed Budget and Justification**

### **JUSTIFICATION**

**FOLLOW THE BUDGET JUSTIFICATION INSTRUCTIONS EXACTLY. USE CONTINUATION PAGES AS NEEDED.**

*Principal Investigator:*

*CDMRP Log Number:*

## **Detailed Budget and Justification**

### **JUSTIFICATION**

**FOLLOW THE BUDGET JUSTIFICATION INSTRUCTIONS EXACTLY. USE CONTINUATION PAGES AS NEEDED.**

*Principal Investigator:*

*CDMRP Log Number:*

## **Detailed Budget and Justification**

### **JUSTIFICATION**

**FOLLOW THE BUDGET JUSTIFICATION INSTRUCTIONS EXACTLY. USE CONTINUATION PAGES AS NEEDED.**

*Principal Investigator:*

*CDMRP Log Number:*

## **Detailed Budget and Justification**

### **JUSTIFICATION**

**FOLLOW THE BUDGET JUSTIFICATION INSTRUCTIONS EXACTLY. USE CONTINUATION PAGES AS NEEDED.**

*Principal Investigator:*

*CDMRP Log Number:*

## **Detailed Budget and Justification**

### **JUSTIFICATION**

**FOLLOW THE BUDGET JUSTIFICATION INSTRUCTIONS EXACTLY. USE CONTINUATION PAGES AS NEEDED.**

*Principal Investigator:*

*CDMRP Log Number:*

## **Detailed Budget and Justification**

### **JUSTIFICATION**

**FOLLOW THE BUDGET JUSTIFICATION INSTRUCTIONS EXACTLY. USE CONTINUATION PAGES AS NEEDED.**

Principal Investigator (Last, first, middle):

---

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel on page 1 of the Detailed Budget and Justification form for the initial budget period.

---

NAME		POSITION TITLE	
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY

---

**RESEARCH AND PROFESSIONAL EXPERIENCE:** Concluding with present position, list in chronological order, previous employment, experience, and honors. Include present membership on any Federal Government public advisory committee. List in chronological order the titles, all authors, and complete references to all publications during the past 3 years and to representative earlier publications pertinent to this application. If the list of publications in the last 3 years exceeds 2 pages, select the most pertinent publications. **PAGE LIMITATIONS APPLY. DO NOT EXCEED 4 PAGES FOR THE ENTIRE BIOGRAPHICAL SKETCH PER INDIVIDUAL.**

Principal Investigator (Last, first, middle):

Principal Investigator (Last, first, middle):

Principal Investigator (Last, first, middle):